Cigna Group Announces Q4 & Full-Year 2024 Results, Sets 2025 Outlook, and Raises Dividend

Cigna Group Reports Strong 2024 Financial Results, Sets 2025 Outlook, and Announces Dividend Increase Global health company The Cigna Group (NYSE: CI) has released its financial results for the fourth quarter and full year 2024, demonstrating continued strength in Evernorth…

Read MoreCigna Group Announces Q4 & Full-Year 2024 Results, Sets 2025 Outlook, and Raises Dividend

Hawthorne Health and RxE2 Collaborate to Enhance Patient Access in Clinical Trials

Hawthorne Health and RxE2 Partner to Transform Community-Based Clinical Trial Delivery Hawthorne Health, a leader in community-based clinical trial delivery, and RxE2, a pioneer in pharmacist-led clinical trial services, have announced a groundbreaking strategic partnership aimed at revolutionizing the way…

Read MoreHawthorne Health and RxE2 Collaborate to Enhance Patient Access in Clinical Trials
Innovaccer

Quanta System Marks 40 Years of Innovation and Unveils Exclusive New Partnership at IMCAS 2025

Quanta System, a leader in medical laser technology, is celebrating a significant milestone in 2025: its 40th anniversary. This momentous occasion not only honors the company’s rich history of technological advancements and breakthroughs but also marks the start of an…

Read MoreQuanta System Marks 40 Years of Innovation and Unveils Exclusive New Partnership at IMCAS 2025

Kyowa Kirin and Swixx BioPharma Expand POTELIGEO® Access for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe

Kyowa Kirin and Swixx BioPharma Expand Access to POTELIGEO® for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe Kyowa Kirin International (KKI), a fully owned subsidiary of Kyowa Kirin Co. Ltd., in partnership with Swixx BioPharma AG, recently…

Read MoreKyowa Kirin and Swixx BioPharma Expand POTELIGEO® Access for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe

Tubulis Doses First Patient in Phase I/IIa Trial of ADC TUB-030 for Advanced Solid Tumors

Tubulis Advances ADC TUB-030 into Clinical Trials for Advanced Solid Tumors Tubulis, a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced a significant milestone today with the dosing of the first patient in its Phase I/IIa clinical trial, 5-STAR 1-01…

Read MoreTubulis Doses First Patient in Phase I/IIa Trial of ADC TUB-030 for Advanced Solid Tumors

Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance

Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance Osta Therapeutics Expands Leadership Team to Tackle Antibiotic Resistance Osta Therapeutics, a biotechnology company focused on developing innovative treatments to combat antibiotic resistance, has announced the appointment…

Read MoreOsta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance

Ethris Announces Positive Phase 1 Results for mRNA Candidate ETH47 in Uncontrolled Asthma

Ethris Announces Promising Phase 1 Clinical Data for mRNA Therapeutic ETH47 in Asthma Treatment Ethris GmbH, a biotechnology pioneer in the development of next-generation RNA therapeutics and vaccines, has announced promising topline results from its completed Phase 1 clinical trial…

Read MoreEthris Announces Positive Phase 1 Results for mRNA Candidate ETH47 in Uncontrolled Asthma

Merz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments

Merz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments Merz Aesthetics, the world’s largest company in aesthetic medicine, has unveiled the findings of its first global study, “Pillars of Confidence: Global Insights on Aesthetics and…

Read MoreMerz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments

Ferrer Recognized for Excellence in Ethical and Responsible Corporate Practices

Ferrer Earns Compliance Leader Verification™ for Exemplary Ethical and Responsible Corporate Practices Ferrer, a globally recognized pharmaceutical company, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere, an organization dedicated to promoting ethical business practices worldwide. This recognition underscores…

Read MoreFerrer Recognized for Excellence in Ethical and Responsible Corporate Practices